MISSISSAUGA, Ontario–(BUSINESS WIRE)–#AVA–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV.V;
OTCQX: CVALF), an advanced medical technologies company, today announces
that it will be showcasing IV Clear at the 2018 Scientific Meeting for
the Association for Vascular Access (“AVA” or the “Meeting”).
Covalon’s IV Clear™ is indicated to cover and protect vascular access
devices used in a wide variety of both acute and alternate care
settings. Its patented combination of chlorhexidine and silver is proven
to have a synergistic effect against some of the most commonly
associated blood stream infection bacteriai and its
skin-sparing silicone adhesive will not cause adhesive-related skin
injury or pain during dressing changesii.
Covalon is also co-sponsoring a presentation on patient advocacy by
Emily Levy, CEO and co-founder of Mighty Well, entitled “Empowering
Vascular Access Specialists: How to Better Inform Patients of Their
Options When It Comes to Their Long-Term Care”. Ms. Levy is a strong
patient advocate and is passionate about advocating for the patient
perspective in healthcare. Ms. Levy will be presenting on Tuesday
September 17th at 11:15am, Room C161.
Covalon will be at AVA, Booth 123, at the Columbus Convention Center in
Columbus, Ohio from September 15th to 17th during all exhibit hours
throughout the meeting.
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world. Covalon’s
patented technologies, products and services address the advanced
healthcare needs of medical device companies, healthcare providers and
individual consumers. Covalon’s technologies are used to prevent, detect
and manage medical conditions in specialty areas such as wound care,
tissue repair, infection control, disease management, medical device
coatings and biocompatibility. To learn more about Covalon, visit www.covalon.com.
i A Laboratory Study of the Synergistic Effect of
Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American
Journal of Infection Control , Volume 43 , Issue 6 , S22
Human Repeat Patch Test Study, DiTizio et al. http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect
the Company’s current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”,
“intend” and statements that an event or result “may”, “will”, “should”,
“could” or “might” occur or be achieved and other similar expressions.
These forward-looking statements involve risk and uncertainties,
including the difficulty in predicting product approvals, acceptance of
and demands for new products, the impact of the products and pricing
strategies of competitors, delays in developing and launching new
products, the regulatory environment, fluctuations in operating results
and other risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or implied
in the forward-looking statements. Many risks are inherent in the
industry; others are more specific to the Company. Investors should
consult the Company’s ongoing quarterly filings for additional
information on risks and uncertainties relating to these forward-looking
statements. Investors should not place undue reliance on any
forward-looking statements. The Company assumes no obligation to update
or alter any forward-looking statements whether as a result of new
information, further events or otherwise.